Literature DB >> 8731007

The impact of patient compliance on drug concentration profile in multiple doses.

W Wang1, F Husan, S C Chow.   

Abstract

Physicians commonly prescribe drugs in a multiple dosage regimen for prolonged therapeutic activity. To study the effect of multiple dosing on drug concentration in blood, researchers often use deterministic models with the assumption that drugs are administered at a fixed dosage, with equal or unequal (fixed) dosing intervals. In practice, many patients do not comply with such a rigid schedule. Hence, two possible scenarios might occur: patients might not take the prescribed dosing amount, resulting in erratic dosing sizes; they might not adhere to the dosing schedule, resulting in erratic dosing times. We propose separate statistical models for these two scenarios and study their impact on blood serum/plasma concentration. With non-compliance, some basic concepts such as steady state need new definition. We provide a rigorous formulation for the principle of superposition which enables us to generalize the concept of steady state. Applying the proposed models, we demonstrate that non-compliance causes the drug concentration time curve to exhibit an increase in fluctuation. The increase in fluctuation due to non-compliance cannot be explained with use of the classical deterministic multiple dose model.

Entities:  

Mesh:

Year:  1996        PMID: 8731007     DOI: 10.1002/(SICI)1097-0258(19960330)15:6<659::AID-SIM207>3.0.CO;2-E

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics.

Authors:  W Wang; S P Ouyang
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

Review 2.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Use of sensitivity functions to characterise and compare the forgiveness of drugs.

Authors:  Patrice Nony; Jean-Pierre Boissel
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.

Authors:  Ayyappa Chaturvedula; Michael J Fossler; Craig W Hendrix
Journal:  J Clin Pharmacol       Date:  2013-11-30       Impact factor: 3.126

6.  Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Authors:  Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  A technical note concerning non-adherence to drug therapy: exact expressions for the mean and variance of drug concentration.

Authors:  Steve Gallivan; Christina Pagel; Martin Utley; Bryony Dean Franklin; Katja Taxis; Nick Barber
Journal:  Health Care Manag Sci       Date:  2008-09

8.  Compliance spectrum as a drug fingerprint of drug intake and drug disposition.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-19       Impact factor: 2.745

9.  Methods to detect non-compliance and reduce its impact on population PK parameter estimates.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Valerie Cosson; Nicolas Frey; Franziska Schaedeli Stark
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-21       Impact factor: 2.745

10.  An alternative method for population pharmacokinetic data analysis under noncompliance.

Authors:  Pankaj Gupta; Matthew M Hutmacher; Bill Frame; Raymond Miller
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-02-26       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.